The EPS projection of Core Laboratories N.V. (NYSE:CLB) for period quarter closed 2016-12-31 is $0.42.
The EPS estimates given 30-days and 1 week ago were $0.42 and $0.42, correspondingly. This number 90 and 60 days before was $0.42 and $0.42 respectively. Yet, from last week, the change in EPS prediction is 0%.
For the quarter ended 2 mean estimate is $0.42 based on 4 EPS estimations. As on 2016-07-20 estimated EPS was $0.35 showing surprise of $0, or 0%. Following the given predictions, the standard deviation is $0.01.
The upgrade count for EPS revisions was 1 a week earlier paralleled to negative revisions of 0. In last 60-days and 1- month, the upgrade in EPS reviews were 1 and 1 correspondingly, though for a quarter and 120-days ago, it was 3 and 3 in that sequence.
The negative reviews of EPS in the last 60-days and 1-month were 1 and 1 in that order. But, a quarter and 120-days ago, this numeral was 0 and 0 correspondingly.
EPS reviews downgrade and upgrade for last 18 days were 1 and 1, correspondingly.
Quarterly Sales Estimates
The mathematical mean of apparent yearly sales of Core Laboratories N.V. (NYSE:CLB) is $168.633 and the median is $163. The estimate is stated by 3 analysts for the fiscal 2017.
The highest yearly projection is $182.9 and lowest sales mark is $160. This results a standard deviation of $12.446.
Almost 3 have reviewed sales target for better in the past week and 3 have downgraded forecasts. Subject to the stated estimates, the intended change in disclosed target from the past week is -0.842%.
Nearly 3 revised sales predictions for better over the past month and 3 have downgraded forecasts. It suggests an average deviation of 3.044% across given estimates.
Just about 3 have revised sales forecast up over the quarter and 3 have downgraded forecasts, hinting to a deviation of 5.067%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...